The CYP19 RS4646 Polymorphism IS Related to the Prognosis of Stage I–II and Operable Stage III Breast Cancer

Xiying Shao; Yong Guo; Xiaohong Xu; Yabing Zheng; Jiwen Wang; Zhanhong Chen; Jian Huang; Ping Huang; Jufen Cai; Xiaojia Wang

doi:10.1371/journal.pone.0121535

Loading metrics

Open Access

Peer-reviewed

Research Article

The CYP19 RS4646 Polymorphism IS Related to the Prognosis of Stage I–II and Operable Stage III Breast Cancer

Xiying Shao,

Affiliation Department of Medical Oncology, The Affiliated Zhejiang Cancer Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China
⨯
Yong Guo,

Affiliation Department of Oncology, The First Affiliated Hospital of Zhejiang Traditional Chinese Medical University, Hangzhou, Zhejiang Province, China
⨯
Xiaohong Xu,

Affiliation Clinical laboratory, The Affiliated Zhejiang Cancer Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China
⨯
Yabing Zheng,

Affiliation Department of Medical Oncology, The Affiliated Zhejiang Cancer Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China
⨯
Jiwen Wang,

Affiliation Department of Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, China
⨯
Zhanhong Chen,

Affiliation Department of Medical Oncology, The Affiliated Zhejiang Cancer Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China
⨯
Jian Huang,

Affiliation Department of Medical Oncology, The Affiliated Zhejiang Cancer Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China
⨯
Ping Huang,

Affiliation Department of Medical Oncology, The Affiliated Zhejiang Cancer Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China
⨯
Jufen Cai,

Affiliation Department of Medical Oncology, The Affiliated Zhejiang Cancer Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China
⨯
Xiaojia Wang

* E-mail: wxiaojia0803@163.com

Affiliation Department of Medical Oncology, The Affiliated Zhejiang Cancer Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China
⨯

The CYP19 RS4646 Polymorphism IS Related to the Prognosis of Stage I–II and Operable Stage III Breast Cancer

Xiying Shao,
Yong Guo,
Xiaohong Xu,
Yabing Zheng,
Jiwen Wang,
Zhanhong Chen,
Jian Huang,
Ping Huang,
Jufen Cai,
Xiaojia Wang

Published: March 20, 2015
https://doi.org/10.1371/journal.pone.0121535

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Breast cancer
Is the Subject Area "Breast cancer" applicable to this article?

Thanks for your feedback.
Estrogens
Is the Subject Area "Estrogens" applicable to this article?

Thanks for your feedback.
Variant genotypes
Is the Subject Area "Variant genotypes" applicable to this article?

Thanks for your feedback.
Alleles
Is the Subject Area "Alleles" applicable to this article?

Thanks for your feedback.
Hormonal therapy
Is the Subject Area "Hormonal therapy" applicable to this article?

Thanks for your feedback.
Lymph nodes
Is the Subject Area "Lymph nodes" applicable to this article?

Thanks for your feedback.
Radiation therapy
Is the Subject Area "Radiation therapy" applicable to this article?

Thanks for your feedback.
Cyclophosphamide
Is the Subject Area "Cyclophosphamide" applicable to this article?

Thanks for your feedback.